ReviewEuropean journal of nuclear medicine and molecular imaging2017
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.
Review in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- EANM guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2021Guideline
- Pooled it
- PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Trial
- Compatibility of different PET/CT criteria in evaluating treatment response and survival in non-small cell lung cancer patients treated with immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The FAP-FDG Integration Score (FFIS): Development and prognostic validation of a dual-tracer PET phenotype for solid tumors.European journal of nuclear medicine and molecular imaging · 2026Article
- 2[18F]-FDG-PET/CT and 2[18F]-FDG-PET/MRI in primary staging of epithelial ovarian cancer - an early interim analysis of a prospective clinical trial.Annals of medicine and surgery (2012) · 2026Article
- coPERCIST: AI-assisted PET-CT response assessment.European journal of nuclear medicine and molecular imaging · 2026Article
- Diagnostic Efficacy of FAPI-PET/CT Versus [Diagnostics (Basel, Switzerland) · 2026Review
- Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical validation of a unified data-driven respiratory motion correction technique inEJNMMI physics · 2026Article
- Systematic double reading for oncological PET/CT scans: insights from a prospective multicentre study in 678 patients.EJNMMI reports · 2025Article
- A fully automated, expert-perceptive image quality assessment system for whole-body [18F]FDG PET/CT.EJNMMI research · 2025Article
- High concordance of PET-CT treatment response evaluation according to PERCIST 1.0 when comparing images reconstructed with OSEM vs. BSREM.Clinical physiology and functional imaging · 2025Article
- Role ofFrontiers in medicine · 2025Article
- Automated Lugano Metabolic Response Assessment inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Metabolic Imaging of Advanced Basal Cell Carcinoma Treated with Sonidegib: A Retrospective Case Series Study.Journal of clinical medicine · 2024Article
- The impact of introducing deep learning based [EJNMMI research · 2024Article
- Treatment of patients with carcinomas in advanced stages with 5-fluorouracil, folinic acid and pyridoxine in tandem.Scientific reports · 2024Article
- Imaging of Pheochromocytomas and Paragangliomas.Endocrine reviews · 2024Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Eighteen years ago, the EORTC PET criteria standardized for the first time response assessment by FDG PET. Response assessment by FDG PET has been further developed and refined by PERCIST (PET response criteria in solid tumors). This review describes the data underlying these two systems for assessing tumor response on FDG PET/CT. It also summarizes recent clinical studies that have compared EORTC criteria and PERCIST with each other as well as with the anatomically based "response criteria in solid tumors" (RECIST). These studies have shown that response assessment by EORTC criteria and PERCIST leads to very similar response classifications. In contrast, there are significant differences between response assessment by PERCIST and RECIST. Preliminary data also suggest that response assessment by PERCIST is better correlated with patient outcome and may be a better predictor for the effectiveness of new anti-cancer therapies than RECIST. If correct, this could have a significant impact on oncologic drug development. However, confirmation of the better predictive value of response assessment by PERCIST by data from randomized trials is still lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.